ibrexafungerp citrate - Profile

What are the generic sources for ibrexafungerp citrate and what is the scope of freedom to operate?

Ibrexafungerp citrate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for ibrexafungerp citrate

International Patents:	59
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ibrexafungerp citrate

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ibrexafungerp citrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes	11,534,433
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes	8,188,085		Y	Y
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes	10,370,406
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes	10,927,142			Y
Glaxosmithkline	BREXAFEMME	ibrexafungerp citrate	TABLET;ORAL	214900-001	Jun 1, 2021		RX	Yes	Yes	10,174,074		Y	Y

International Patents for ibrexafungerp citrate

Country	Patent Number	Title	Estimated Expiration
Cyprus	1125272
Denmark	3247711
Eurasian Patent Organization	036874	НОВЫЕ СОЛИ И ПОЛИМОРФЫ SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)
Eurasian Patent Organization	201791645	НОВЫЕ СОЛИ И ПОЛИМОРФЫ SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)
European Patent Office	3247711	NOUVEAUX SELS ET POLYMORPHES DE SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078)

Ibrexafungerp Citrate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Ibrexafungerp citrate is an investigational antifungal agent developed by Scynexis Inc. targeting invasive fungal infections, including resistant strains. Its unique mechanism as a glucan synthase inhibitor offers potential differentiation from existing antifungals. The drug’s US regulatory status is pivotal: as of early 2023, it has received FDA Breakthrough Therapy designation for certain indications, with Phase 3 trials ongoing for vulvovaginal candidiasis and other invasive fungal infections. This article delineates its investment landscape, current market dynamics, and projected financial trajectory, providing a comprehensive assessment for stakeholders.

---

What is Ibrexafungerp Citrate and Its Therapeutic Focus?

Attribute	Details
Active Compound	Ibrexafungerp (formerly SCY-078), citrate salt form
Therapeutic Class	Oral and intravenous antifungal, glucan synthase inhibitor
Primary Indications	Vulvovaginal candidiasis, invasive candidiasis, pulmonary aspergillosis
Mechanism of Action	Inhibits fungal cell wall synthesis by targeting beta-(1,3)-glucan synthase
Development Status	Approved in some regions for specific indications; FDA Phase 3 for others

Source: 1

Market Landscape and Competitive Positioning

Global Fungal Infection Market Overview

Segment	Market Size (2022, USD billion)	CAGR (2022–2027)	Key Players
Invasive Fungal Infections	$3.0	6%	Pfizer, Gilead, Scynexis, Merck, Basilea
Vulvovaginal Candidiasis	$1.4	4.5%	Pfizer (Diflucan), GSK (Sporanox), Scynexis (IBX-106)

Note: The market is projected to reach approx. $4.8 billion by 2027 (source: MarketWatch).

Competitive Dynamics

Competitor	Key Drugs	Patent Expiry	Formulation	Market Focus	Differentiators
Pfizer	Fluconazole, Itraconazole	2025-2027	Oral, intravenous	Vaginal, systemic fungal infections	Established market, broad spectrum
Gilead Sciences	Amphotericin B, others	2023–2029	Intravenous	Severe invasive fungal infections	Potency, existing clinical infrastructure
Basilea Pharma	Isavuconazole	2027	Oral, IV	Invasive aspergillosis, mucormycosis	Second-generation azole, broad approval
Scynexis Inc.	Ibrexafungerp (IBX-106)	Patent-expiring soon (2028)	Oral, IV	Emerging standard for resistant strains	Oral bioavailability, activity against resistant fungi

Market Entry and Differentiator Prospects

• Unique Mechanism: First-in-class glucan synthase inhibitor with oral and IV forms.
• Resistant Strains: Demonstrated efficacy against azole- and echinocandin-resistant fungi.
• Regulatory Designations: FDA Breakthrough Therapy, fast-track qualification accelerates approval prospects.
• Pricing and Reimbursement: Projected premium pricing for unmet needs.

Investment Scenario

Projected Revenue Streams

Indication	Approval Status	Estimated Launch Year	Market Share Potential	Price Point (USD per treatment)	Revenue Estimate (USD millions) (2025–2030)
Vulvovaginal Candidiasis	Phase 3 trials ongoing	2023–2024	20–30% of identified cases	200–300	~$500–800
Invasive Candidiasis & Aspergillosis	Pending approval in US/EU	2024–2025	10–15% of severe cases	300–400	~$300–600
Resistant Strains (Off-label use)	Growing off-label use	2025+	N/A	Premium (>=400)	Incremental revenue

Note: Revenue estimates are conservative, subject to phase 3 trial outcomes and regulatory timelines.

Cost Structure and Investment Requirements

Cost Component	USD Millions (per annum)	Notes
R&D Expenses	50–70	Phase 3 trials, regulatory filings, manufacturing scale-up
Commercial Operations	20–40	Launch, marketing, reimbursement negotiations
Manufacturing & Supply Chain	30–50	Scale-up, quality control
Total Annual Investment	100–160	Critical for market penetration

Potential Risks

Risk Factor	Impact	Mitigation
Regulatory Delays	Postponed launches, revenue loss	Engage with agencies early, robust trial data
Market Competition	Marginalized market share	Demonstrate differentiation, broad IP coverage
Manufacturing Challenges	Supply shortages, quality issues	Diversify supply chain, scalable manufacturing processes
Pricing & Reimbursement Barriers	Reduced margins	Early payer engagement, health economic data

---

Market Dynamics

Regulatory Policies and Approvals

• FDA: Ibrexafungerp received Breakthrough Therapy designation for invasive candidiasis (2020).
• EMA: Rolling review ongoing for key indications.
• Orphan Drug Designation: Applies in select indications, expediting approval and providing incentives.

Pricing and Reimbursement Environment

Region	Reimbursement Landscape	Expected Price Range (USD)	Key Factors
US	Medicare/Medicaid/Private payers	200–400 per treatment	Value-based assessments, demonstration of unique efficacy
EU	National Health Systems	150–350 per course	Reimbursement negotiations, health technology assessments
Asia-Pacific	Varied, emerging markets	100–250 per course	Cost-effectiveness evaluations, access programs

Key Market Drivers

• Rising incidence of invasive fungal infections, especially in immunocompromised and COVID-19 patients.
• Growing antifungal resistance, reducing efficacy of existing classes.
• Increased regulatory focus on novel mechanisms and formulations.
• Rising healthcare expenditure and awareness.

---

Financial Trajectory: Forecasts and Valuation Perspectives

Scenario-Based Financial Projections (2023-2030)

Year	Estimated Revenue (USD millions)	Key Assumptions	Notes
2023	0	Regulatory review, pre-approval activities	No sales; phase 3 trials ongoing
2024	50–100	Approvals for vulvovaginal candidiasis	Launch in US/EU
2025	200–400	Broader indications, invasive fungal infections	Market expansion, increased uptake
2026	350–700	Growing off-label and resistant strains use	Market stabilization, competitive positioning
2027	500–900	Possible peak if approvals for multiple indications	Full market penetration, optimal pricing
2028+	Stabilization/decline	Patent expiration pressures	Biosimilar entry, pricing reductions

Valuation Considerations

• Market Penetration Rate Assumptions: 10–30% for initial indications.
• Discount Rate: 10–12% reflective of risk and sector volatility.
• NPV Estimates: Depending on assumptions, potential valuation ranges from USD 1 billion to USD 3 billion for Scynexis and partners.

---

Comparison with Existing Antifungals

Drug Class	Examples	Route	Indications	Resistance Profile	Market Share (2022)	Key Differentiators
Azoles	Fluconazole, Itraconazole	Oral, topical	Candidiasis, cryptococcosis	Resistance emerging in non-albicans species	Dominant	Cost-effective, well-established
Echinocandins	Caspofungin, Micafungin	IV	Invasive candidiasis, aspergillosis	Resistance rare but increasing	Significant	Potency, IV-only
Polyenes	Amphotericin B	IV	Severe fungal infections	Toxicity concerns	Niche	Broad spectrum, toxic profile
Novel Agents	Ibrexafungerp, rezafungerrp	Oral, IV	Next-generation treatment options	Designed to combat resistance	Emerging niche	Oral bioavailability, activity against resistant strains

---

Key Takeaways

• Ibrexafungerp citrate presents a significant innovation in antifungal therapy, leveraging a unique mechanism with activity against resistant strains.
• Market growth driven by increasing fungal infections, resistance issues, and unmet medical needs.
• Regulatory pathways, including FDA breakthrough designations, are accelerating approval timelines.
• Financial projections indicate potential for rapid revenue ramp-up post-approval, with peak revenues possible by 2027.
• Risks remains, including regulatory delays, market competition, and pricing pressures, but strategic positioning can mitigate these.

---

FAQs

1. What are the primary indications for Ibrexafungerp citrate?
   Currently, its primary focus is on vulvovaginal candidiasis and invasive candidiasis, with ongoing trials for invasive aspergillosis and resistant fungal infections.

2. How does Ibrexafungerp differ from existing antifungals?
   As a glucan synthase inhibitor, it offers oral administration, activity against resistant strains, and a novel mechanism compared to azoles and polyenes.

3. What are the main regulatory milestones to watch?
   FDA approval for key indications, potential EMA approval, and expansion of orphan or breakthrough therapy designations.

4. What are the key market risks?
   Regulatory delays, competition from established agents, biosimilar entry post-patent expiry, and reimbursement challenges.

5. What is the expected timeline for revenue realization?
   Likely post-2024, contingent on successful regulatory approval and market access strategies, with peak revenues expected by 2027.

---

References

1. Scynexis Inc. Ibrexafungerp Product Overview. https://www.scynexis.com/products/ibrexafungerp/
2. MarketWatch Reports on Global Fungal Infection Market, 2022.
3. U.S. FDA Breakthrough Therapy Designations, CDC fungal infection data, 2020–2023.
4. Industry publications and clinical trial registries, clinicaltrials.gov.

---

This comprehensive assessment underscores Ibrexafungerp citrate's potential as a transformative antifungal agent, positioning it favorably for strategic investments and market expansion.